HLA-B and plasma cell myeloma: B cell-specific transcription factor BOB1-HLA-B*07:02-TCR-engineered T cells was efficiently shown to lyse primary B-cell leukemia, mantle cell lymphoma, and multiple myeloma in vitro and had in vivo antitumor reactivity in a multiple myeloma xenograft mouse model.